Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 4/20 | 0.53 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.53 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.53 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4191188 | 0.86 | MAOA (0.47) | EPHX1MAOASMN1; SMN2NPSR1 | |
| SCHEMBL18629569 | 0.81 | NPSR1 (0.56) | EPHX1EPHX2SMN1; SMN2NPSR1 | |
| SCHEMBL6497863 | 0.80 | MAPK1 (0.44) | CHRM3CHRM5SIGMAR1SMN1; SMN2NPSR1 | |
| SCHEMBL9029685 | 0.79 | EPHX1 (0.48) | EPHX1POLBMAOASMN1; SMN2 | |
| SCHEMBL9027751 | 0.79 | EPHX1 (0.48) | EPHX1POLBMAOASMN1; SMN2 | |
| SCHEMBL9027748 | 0.79 | EPHX1 (0.48) | EPHX1POLBMAOASMN1; SMN2 | |
| SCHEMBL1908699 | 0.79 | MAOA (0.43) | EPHX1MAOASMN1; SMN2NPSR1 | |
| SCHEMBL617591 | 0.79 | GNAI3 (0.62) | EPHX1GNAI3GNAO1GNAI1POLB | |
| SCHEMBL4503819 | 0.78 | MAOA (0.42) | MAOASMN1; SMN2NPSR1 | |
| SCHEMBL21198215 | 0.78 | SMYD3 (0.49) | MAOASMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023163527-A1 | NOVEL COMPOUND HAVING INHIBITORY ACTIVITY AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE, AND USES THEREOF | 주식회사 카나프테라퓨틱스 | 2023-08-31 | — | — | WO | disclosed |
| WO-2023163527-A1 | NOVEL COMPOUND HAVING INHIBITORY ACTIVITY AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE, AND USES THEREOF | 주식회사 카나프테라퓨틱스 | 2023-08-31 | — | — | WO | disclosed |
| US-20050009843-A1 | Medicine for inhibiting drug elimination pump | TRINE PHARMACEUTICALS, INC. | 2005-01-13 | — | — | US | disclosed |
| EP-1389463-A1 | MEDICINE FOR INHIBITING DRUG ELIMINATION PUMP | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009843-A1 | Medicine for inhibiting drug elimination pump | ABCB11, ATP6AP1, HRH2 | EPHX1 1332/4885GNAI3 3279/4885GNAO1 2376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.